---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-002047"
form_type: "8-K"
ticker: "VYGR"
cik: "0001640266"
company_name: "Voyager Therapeutics, Inc."
filed_at: "2023-01-09T23:59:59+00:00"
generated_at: "2026-06-20T17:54:33.423330+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Voyager Therapeutics Enters Gene Therapy Collaboration with Neurocrine for Up to $1.96B in Milestones

## Summary
- Neurocrine pays Voyager $136M upfront (net of $39M stock purchase) for GBA1 and three CNS gene therapy programs.
- Voyager eligible for up to $985M in development milestones for GBA1 and up to $175M per New Discovery Program.
- Commercial milestones up to $950M per GBA1 product and $275M per New Discovery product; tiered royalties also apply.
- Neurocrine purchases 4,395,588 shares of Voyager common stock at $8.88/share (~$39M) under a separate stock purchase agreement.
- Voyager shifts Huntington's disease program to vectorized siRNA approach using proprietary TRACER capsids.

## SEC filing metadata
- accession: 0001104659-23-002047
- form_type: 8-K
- ticker: VYGR
- cik: 0001640266
- company_name: Voyager Therapeutics, Inc.
- filed_at: 2023-01-09T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1640266/000110465923002047/0001104659-23-002047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1640266/000110465923002047/tm232664d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-002047
- JSON: https://secwatch.observer/filing/0001104659-23-002047.json
- Plain text: https://secwatch.observer/filing/0001104659-23-002047.txt

## Key facts
- Material Agreements
  Voyager Therapeutics, Inc. entered into Collaboration and License Agreement with Neurocrine Biosciences, Inc. (effective 2023-01-08).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Neurocrine Biosciences, Inc.
  - Effective: 2023-01-08
  source text: On January 8, 2023 (the “Agreement Date”), Voyager Therapeutics, Inc. (the “Company”) entered into a Collaboration and License Agreement (the “Collaboration Agreement”) with Neurocrine Biosciences, Inc. (“Neurocrine”) for the research, development, manufacture and commercialization of gene therapy products directed to the gene that encodes glucosylceramidase beta 1 (“GBA1”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1640266/000110465923002047/0001104659-23-002047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.